Results 111 to 120 of about 8,133 (247)

Incretins and diabetes mellitus type 2 - from pathophysiology to therapeutic treatment [PDF]

, 2014
Moderni terapijski pristup liječenju šećerne bolesti tipa 2 usmjeren je na povećanje razine inkretinskih hormona u cirkulaciji. Inkretini su endogeni regulatorni peptidi koje izlučuju stanice crijeva i koji potiču otpuštanje inzulina, inhibiraju ...
Ranđelović, Karla
core  

Evaluating EndoC βH5 pseudoislets as a model for human islet transplantation

Diabetic Medicine, EarlyView.
Abstract Aims The EndoC βH5 cell line represents a promising human β‐cell model for preclinical diabetes research. Indeed, EndoC βH5 cells aggregate into islet‐like organoids, secrete insulin in a glucose‐dependent manner, and express a variety of β‐cell functional markers.
Lydia F. Daniels Gatward, William T. Blackstone Whines, Tzu‐Wen Hong, Rosie Sullivan, Jessica Starikova, Adya Lonsane, Ryea Arora, Victoria Salem, Min Zhao, Peter M. Jones, Aileen F. J. King, Shanta J. Persaud   +11 more
wiley   +1 more source

Dietary fibers to boost endogenous GLP-1 secretion and satiety: a scoping review

Frontiers in Endocrinology
BackgroundDietary fibers can stimulate endogenous glucagon−like peptide−1 (GLP−1) secretion through microbial fermentation and gut hormone signaling, potentially enhancing satiety and supporting weight management.
Jelle C. B. C. de Jong, Milou G. W. Lentjes, Karleen F. Pietersma, Wilrike J. Pasman, Suzan Wopereis, Suzan Wopereis, Femke P. M. Hoevenaars   +6 more
doaj   +1 more source

GLP‐1‐Based Therapies in Type 1 Diabetes: Emerging Evidence on Cardiovascular, Renal, and Safety Outcomes

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Individuals living with type 1 diabetes (T1D) are at increased risk for cardiovascular (CV) and renal complications, yet therapeutic strategies specifically targeting cardiorenal risk reduction in this population remain limited. The role of glucagon‐like peptide‐1 (GLP‐1)‐based therapies in T1D remains unclear.
Anastasios Tentolouris, Djordje S. Popovic, Alexandros L. Liarakos, Alexandros Briasoulis, Nikolaos Papanas, Theocharis Koufakis   +5 more
wiley   +1 more source

Periodontitis and metabolic diseases (diabetes and obesity): Tackling multimorbidity

Periodontology 2000, EarlyView., 2023
Abstract Noncommunicable diseases (NCDs) are multifactorial, long‐term, chronic conditions that represent a burden to health‐care systems worldwide as they can only be controlled rather than cured; hence, they require long‐term care. With the exponential increase in NCDs, the occurrence of individuals presenting with more than one chronic disease is ...
Crystal Marruganti, Jean E. Suvan, Francesco D'Aiuto   +2 more
wiley   +1 more source

Molecular mapping and functional validation of GLP-1R cholesterol binding sites in pancreatic beta cells

eLife
G protein-coupled receptors (GPCRs) are integral membrane proteins which closely interact with their plasma membrane lipid microenvironment. Cholesterol is a lipid enriched at the plasma membrane with pivotal roles in the control of membrane fluidity and
Affiong Ika Oqua, Kin Chao, Liliane El Eid, Lisa Casteller, Billy P Baxter, Alba Miguéns-Gómez, Sebastian Barg, Ben Jones, Jorge Bernardino de la Serna, Sarah L Rouse, Alejandra Tomas   +10 more
doaj   +1 more source

Tirzepatide Persistence and Associated Changes in Clinical Outcomes in US Adults With Obesity or Overweight: A 6‐Month Claims Database Analysis

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Tirzepatide is a once‐weekly glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) approved in the US for the treatment of Type 2 diabetes (T2D), weight loss and obstructive sleep apnoea. This study aimed to assess the utilisation and effectiveness of tirzepatide among individuals in a large ...
Theresa Hunter Gibble, Malvika Venkataraman, Donna Mojdami, Carlos Vallarino, Grace Stockbower, Michael Grabner, Mythili Ananth, Karishma Desai   +7 more
wiley   +1 more source

Real‐World Effectiveness and Treatment Patterns of Tirzepatide in a Large UK Digital Health Cohort

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Tirzepatide has demonstrated substantial weight‐loss efficacy in clinical trials, but real‐world evidence from routine digital prescribing remains limited. Methods We conducted a retrospective cohort study of adults initiating tirzepatide for obesity via a UK digital prescribing service between March 2024 and July 2025. Linked order‐
Onayomi Rosenior‐Patten, Zoe Lees, Rebecca Rowe, Safia Hussain, Ehtasham Ahmad, Edward Brooke, Sophie Dix, Catriona Maybury   +7 more
wiley   +1 more source

Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early‐Phase Clinical Trials

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims The management of the disease of obesity has been transformed by incretin‐based therapies; however, additional and alternative therapeutic strategies are needed to address its biological complexity. This narrative review examines the physiology of amylin and the emerging role of amylin‐based therapies in obesity management.
Abdulhameed Alhazmi, Carel W. le Roux
wiley   +1 more source

Early Weight Regain After GLP‐1 Receptor Agonist Discontinuation: Mechanisms and Implications for Treatment De‐Escalation Strategies

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have transformed the pharmacological management of obesity, producing substantial and sustained weight loss during active treatment. However, discontinuation of therapy is frequently followed by significant weight regain, raising important questions regarding the durability of treatment ...
M. A. Damhof, F. H. van Bruggen, E. N. van Roon   +2 more
wiley   +1 more source